Latest Breaking News On - Institutional trading of apellis pharmaceuticals - Page 1 : vimarsana.com

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to Post Q2 2024 Earnings of ($0.42) Per Share, Wedbush Forecasts

Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS)

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.5% After Analyst Downgrade

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 3.5% during trading on Monday after Mizuho lowered their price target on the stock from $60.00 to $52.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $48.01 and last traded at $48.11. 88,800 shares changed hands during trading, […]

Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells 4,000 Shares of Stock

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by Mizuho

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Sees Large Drop in Short Interest

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 10,670,000 shares, a decline of 11.3% from the January 15th total of 12,030,000 shares. Based on an average daily trading volume, of 2,100,000 shares, the days-to-cover […]

Apellis Pharmaceuticals (NASDAQ:APLS) Raised to "Buy" at Jefferies Financial Group

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by Robert W. Baird

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “outperform” rating reiterated by Robert W. Baird in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $81.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 21.68% from the stock’s previous close. […]

Oppenheimer Raises Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $79.00

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its target price boosted by stock analysts at Oppenheimer from $75.00 to $79.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 20.78% from the […]

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down Following Insider Selling

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) gapped down before the market opened on Tuesday following insider selling activity. The stock had previously closed at $65.45, but opened at $63.81. Apellis Pharmaceuticals shares last traded at $63.90, with a volume of 195,943 shares changing hands. Specifically, CAO James George Chopas sold 864 […]